VARIBAR NECTAR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VARIBAR NECTAR (VARIBAR NECTAR).
Barium sulfate is a radiopaque contrast agent that coats the mucosal surface of the gastrointestinal tract, allowing radiographic visualization of anatomical structures by attenuating X-rays.
| Metabolism | Barium sulfate is not metabolized; it is eliminated unchanged in feces. |
| Excretion | Varibar Nectar is a barium sulfate suspension used as a radiographic contrast agent. It is not absorbed systemically and is eliminated entirely via the gastrointestinal tract. Following oral administration, the majority (~95-100%) is excreted unchanged in the feces within 24-72 hours. Minimal renal excretion (<1%) occurs only if absorbed, which is negligible in patients with intact GI mucosa. |
| Half-life | Not applicable as Varibar Nectar is not systemically absorbed. The elimination half-life from the GI tract is approximately 4-6 hours, corresponding to the transit time through the small and large intestine. This is not a terminal half-life in the classic pharmacokinetic sense. |
| Protein binding | Not applicable, as Varibar Nectar is not systemically absorbed. It remains within the GI lumen and does not bind to plasma proteins. |
| Volume of Distribution | Not applicable; Varibar Nectar is confined to the GI lumen and does not distribute into body tissues. Apparent volume of distribution is essentially the volume of the GI tract (approximately 1-2 L in adults), but this is not a classic Vd measurement. |
| Bioavailability | Oral: 0% systemic bioavailability, as barium sulfate is not absorbed. It acts locally within the GI tract. There is no intravenous or other parenteral formulation; all routes are for GI imaging only. |
| Onset of Action | Oral administration: Radiographic visualization of the esophagus, stomach, and duodenum begins immediately upon ingestion, with optimal coating achieved within 1-2 minutes. For double-contrast studies, onset is within 30 seconds to 2 minutes. |
| Duration of Action | The duration of radiographic visualization varies by region: esophageal coating persists for 1-3 minutes; gastric coating for 10-30 minutes; small bowel opacification for 30-60 minutes. Complete GI clearance occurs within 24-72 hours. Note: Barium may cause constipation; adequate hydration is recommended. |
| Molecular Weight | 1600 |
For radiographic examination of the esophagus, stomach, and duodenum: 30-90 mL of a 40-70% w/v barium sulfate suspension administered orally. For double-contrast studies, 100-200 mL of a 250% w/v suspension may be used. Route: oral. Frequency: single dose prior to imaging.
| Dosage form | SUSPENSION |
| Renal impairment | No dose adjustment required for renal impairment as barium sulfate is not significantly absorbed and is excreted fecally. |
| Liver impairment | No dose adjustment required for hepatic impairment as barium sulfate is not metabolized by the liver. |
| Pediatric use | For upper GI series: 1-2 mL/kg of a 40-70% w/v suspension, maximum 60 mL. For double-contrast: 2-4 mL/kg of a 250% w/v suspension, maximum 100 mL. Administer orally as single dose. |
| Geriatric use | No specific dose adjustment needed in elderly patients; use lowest effective volume to minimize risk of aspiration or constipation. Ensure adequate hydration. |
| 1st trimester | No controlled data in human pregnancy. Animal studies not available. Use only if clearly needed and potential benefit justifies potential risk to fetus. |
| 2nd trimester | No controlled data in human pregnancy. Use only if clearly needed and potential benefit justifies potential risk to fetus. |
| 3rd trimester | No controlled data in human pregnancy. Use only if clearly needed and potential benefit justifies potential risk to fetus. |
Clinical note
Comprehensive clinical and safety monograph for VARIBAR NECTAR (VARIBAR NECTAR).
| Placental transfer | No data available on placental transfer. Based on molecular weight (low evidence), possible transfer cannot be excluded. |
| Breastfeeding | It is not known whether this drug is excreted in human milk. Due to limited data, caution should be exercised when administered to a nursing woman. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for the drug and any potential adverse effects on the breastfed child. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Known hypersensitivity to Varibar Nectar or any of its excipients
| Precautions | Risk of aspiration leading to pneumonitis or granuloma formation, Acute hypersensitivity reactions including anaphylaxis, Constipation or fecal impaction, especially in elderly or dehydrated patients, Risk of barium leakage into peritoneum or mediastinum if perforation is suspected, Intravasation (rare but serious) leading to embolization |
| Food/Dietary | Avoid concurrent intake of antacids or oral medications containing bismuth (e.g., Pepto-Bismol) as they may interfere with coating. No specific food interactions; maintain NPO prior to study. Post-procedure, increase fluid intake to prevent barium impaction. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | VARIBAR NECTAR (barium sulfate) is not absorbed systemically and does not cross the placenta. No teratogenic effects are expected. Safe in all trimesters. |
| Fetal Monitoring | No specific monitoring required. Assess for aspiration risk and bowel obstruction. |
| Fertility Effects | No known effects on fertility. Not systemically absorbed. |
| Clinical Pearls | Varibar Nectar is a barium sulfate suspension used for fluoroscopic esophageal and upper GI studies. Ensure patient has NPO status for at least 4 hours before study. Administer with a straw to control flow rate. Observe for aspiration; have suction available. Use with caution in patients with suspected perforation, severe dysphagia, or risk of aspiration. |
| Patient Advice | Do not eat or drink for at least 4 hours before the procedure. · Inform your doctor if you have had any allergic reaction to barium or contrast agents. · You may experience constipation after the exam; drink plenty of fluids unless otherwise instructed. · Notify your doctor if you develop severe abdominal pain, inability to pass stool, or signs of allergic reaction. |